This litigation has concluded and we are proud to report that our clients' claims have been successfully resolved. The amounts of all individual client recoveries are confidential, both by settlement agreement and by attorney-client privilege. MLG is no longer accepting cases involving this product.
Invokana® (canagliflozin) is a drug prescribed to treat Type 2 diabetes. It belongs to a new class of drugs referred to as “Sodium Glucose co-transporter 2 (SGLT2) inhibitors.” Approved for sale by the FDA in 2013, Invokana® was the first of this new class to be sold in the United States. Invokana® and its related drugs, Invokamet and Invokamet XR are manufactured and sold by Johnson & Johnson and its subsidiary Janssen Pharmaceuticals. Other SGLT2 inhibitors - Farxiga® and Xigduo® XR (Astra Zeneca) and Jardiance® and Glyxambi® (Boehringer Ingelheim & Eli Lilly) – were subsequently approved for sale in the U.S. Each of these drugs comes in two forms: one as the sole drug and the other as a combination drug that includes the branded drug.
In 2017 the FDA issued a Drug Safety Communication confirming that patients taking Invokana®, Invokamet® and Invokamet® XR are at an increased risk of leg and foot amputations and that the manufacturers (Johnson & Johnson and its subsidiary Janssen Pharmaceuticals) must include a “Black Box Warning” on the drugs’ labeling. The Drug Safety Communication was issued after the FDA reviewed data from two different clinical trials – the CANVAS and CANVAS-R studies. These data demonstrated that diabetes patients treated with Invokana®, Invokamet® and Invokamet® XR were twice as likely to require leg and foot amputations than those diabetes patients who were taking placebo (a non-drug). Also, on August 29, 2018 the FDA issued an urgent Safety Announcement to health care professionals and their patients. The Alert warned about the association between Invokana®, Invokamet®, Invokamet® XR, Jardiance®, Farxiga® and other SGLT2 diabetes medications and Fournier’s Gangrene, a life-threatening genital infection that can affect both men and women.
This litigation has concluded and we are proud to report that our clients' claims have been successfully resolved. The amounts of all individual client recoveries are confidential, both by settlement agreement and by attorney-client privilege. MLG is no longer accepting cases involving this product.